L Y S Yamakami1, P C Serafini1, D B de Araujo2, E Bonfá3, E P Leon3, E C Baracat1, C A Silva4. 1. Department of Gynecology. 2. Division of Rheumatology Department of Rheumatology, Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil. 3. Division of Rheumatology. 4. Division of Rheumatology Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil clovis.silva@hc.fm.usp.br.
Abstract
OBJECTIVE: The objective of this paper is to evaluate ovarian reserve in primary antiphospholipid syndrome (PAPS) women and the association between ovarian reserve tests and clinical and laboratorial parameters, and anti-corpus luteum antibody (anti-CoL). METHODS: We screened 85 female patients between 18 to 40 years old with APS. Of these, 67 patients were excluded because of association with other autoimmune diseases (n = 42), contraindication or unwillingness to stop hormonal contraceptive (n = 21), current pregnancy or breastfeeding (n = 3) and previous ovarian surgery (n = 1). Therefore, a cross-sectional study was conducted in 18 PAPS patients and 24 healthy women. They were evaluated at early follicular phase with measurement of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and anti-Müllerian hormone (AMH) and sonographic antral follicle count (AFC). Serum measurement of anti-CoL was determined by immunoblot analysis. All analyses were performed after at least six months from the last intake of hormonal contraceptive and resumption of menstruation. RESULTS: The mean age was comparable in PAPS and controls (33.0 ± 5.0 vs. 30.4 ± 7.0 years; p = 0.19). Regarding ovarian reserve tests, the frequencies of low AFC (≤10) (56% vs. 22%, p = 0.04) and very low AFC (≤5) (37% vs. 9%, p = 0.04) were significantly higher in PAPS patients than controls. Trends of higher frequencies of reduced (<1.0 ng/ml), low (<0.5 ng/ml) and negligible (<0.2 ng/ml) AMH levels were found in PAPS patients (p = 0.08, p = 0.07 and p = 0.07, respectively). FSH, LH and estradiol were similar in patients and controls. There was no association between low ovarian reserve and specific types of antiphospholipid antibodies. Anti-CoL was solely observed in PAPS patients (11% vs. 0%; p = 0.177) and was not related to ovarian reserve tests. CONCLUSION: Women suffering from PAPS possessed reduced ovarian reserve, with prevalence greater than 50%.
OBJECTIVE: The objective of this paper is to evaluate ovarian reserve in primary antiphospholipid syndrome (PAPS) women and the association between ovarian reserve tests and clinical and laboratorial parameters, and anti-corpus luteum antibody (anti-CoL). METHODS: We screened 85 female patients between 18 to 40 years old with APS. Of these, 67 patients were excluded because of association with other autoimmune diseases (n = 42), contraindication or unwillingness to stop hormonal contraceptive (n = 21), current pregnancy or breastfeeding (n = 3) and previous ovarian surgery (n = 1). Therefore, a cross-sectional study was conducted in 18 PAPS patients and 24 healthy women. They were evaluated at early follicular phase with measurement of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and anti-Müllerian hormone (AMH) and sonographic antral follicle count (AFC). Serum measurement of anti-CoL was determined by immunoblot analysis. All analyses were performed after at least six months from the last intake of hormonal contraceptive and resumption of menstruation. RESULTS: The mean age was comparable in PAPS and controls (33.0 ± 5.0 vs. 30.4 ± 7.0 years; p = 0.19). Regarding ovarian reserve tests, the frequencies of low AFC (≤10) (56% vs. 22%, p = 0.04) and very low AFC (≤5) (37% vs. 9%, p = 0.04) were significantly higher in PAPS patients than controls. Trends of higher frequencies of reduced (<1.0 ng/ml), low (<0.5 ng/ml) and negligible (<0.2 ng/ml) AMH levels were found in PAPS patients (p = 0.08, p = 0.07 and p = 0.07, respectively). FSH, LH and estradiol were similar in patients and controls. There was no association between low ovarian reserve and specific types of antiphospholipid antibodies. Anti-CoL was solely observed in PAPS patients (11% vs. 0%; p = 0.177) and was not related to ovarian reserve tests. CONCLUSION:Women suffering from PAPS possessed reduced ovarian reserve, with prevalence greater than 50%.
Authors: Amy L Winship; Lauren R Alesi; Sneha Sant; Sherene Loi; Karla J Hutt; Jessica M Stringer; Aldana Cantavenera; Teharn Hegarty; Carolina Lliberos Requesens; Seng H Liew; Urooza Sarma; Meaghan J Griffiths; Nadeen Zerafa; Stephen B Fox; Emmaline Brown; Franco Caramia; Pirooz Zareie; Nicole L La Gruta; Kelly-Anne Phillips; Andreas Strasser Journal: Nat Cancer Date: 2022-08-25
Authors: Fernando Henrique Carlos de Souza; Clovis Artur da Silva; Lucas Yugo Shiguehara Yamakami; Vilma dos Santos Trindade Viana; Eloisa Bonfá; Samuel Katsuyuki Shinjo Journal: Clin Rheumatol Date: 2015-09-07 Impact factor: 2.980
Authors: Ali Şahin; Savaş Karakuş; Yunus Durmaz; Çağlar Yıldız; Hüseyin Aydın; Ahmet Kıvanç Cengiz; Duygu Güler Journal: Int J Rheumatol Date: 2015-05-12
Authors: Eirini Papadimitriou; Georgios Boutzios; Alexander G Mathioudakis; Nikos F Vlahos; Panayiotis Vlachoyiannopoulos; George Mastorakos Journal: PLoS One Date: 2022-07-27 Impact factor: 3.752